carnitine/neoplasms

BACKGROUND OF THE INVENTION Fatty acids are catabolized, mostly, in the mitochondria through the .beta.-oxidation pathway, where the carnitine palmitoyltransferase (CPT) system plays a key role in transporting long chain fatty acids (FAs) from the cytoplasm to the mitochondrial matrix. The CPT

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5

The present invention relates to the treatment of cancers using aplidine or related compounds which are aplidine analogs. BACKGROUND OF INVENTION Cancer comprises a group of malignant neoplasms that can be divided into two categories, carcinoma, comprising a majority of the cases observed in the

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5

BACKGROUND Undesired weight loss, particularly lean mass loss is a relatively common occurrence in critical illness, and has a significant impact on morbidity and mortality. This is particularly true in cancer patients, where such mass losses can become treatment-limiting, and thus impact overall

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5

BACKGROUND Undesired weight loss, particularly lean mass loss is a relatively common occurrence in critical illness, and has a significant impact on morbidity and mortality. This is particularly true in cancer patients, where such mass losses can become treatment-limiting, and thus impact overall

This invention relates generally to promoting the healing process of physiological disorders or diseases and, more specifically to nutrient compositions that promote the effectiveness or efficiency of the immune system. Physiological disorders and diseases affect millions of individuals each year.

This invention relates generally to promoting the healing process of physiological disorders or diseases and, more specifically to nutrient compositions that promote the effectiveness or efficiency of the immune system. Physiological disorders and diseases affect millions of individuals each year.

CROSS REFERENCE This application claims priority to U.S. patent application Ser. No. 13/043,056 filed Mar. 8, 2011 and U.S. patent application Ser. No. 13/043,216 filed Mar. 8, 2011, the specifications of which are incorporated herein by reference in their entirety. BACKGROUND OF THE INVENTION The

BACKGROUND OF THE INVENTION The present invention features novel dietary supplements, which may benefit individuals suffering from various conditions such as nutritional deficiencies, vitamin deficiencies, aging, cancer, dementia/Alzheimer's disease, high blood pressure, high cholesterol, coronary

BACKGROUND OF THE INVENTION The present invention features novel dietary supplements, which may benefit individuals suffering from various conditions such as nutritional deficiencies, vitamin deficiencies, aging, cancer, dementia/Alzheimer's disease, high blood pressure, high cholesterol, coronary

The present invention relates to an enteral nutritional supplement for persons with cancer who are not currently undergoing radiation therapy and/or chemotherapy. Cancer patients typically undergo intermittent periods of chemotherapy and/or radiation therapy during which their nutritional needs are

FIELD OF THE INVENTION This invention relates to a method for increasing the intestinal absorption, cellular concentration, biliary secretion, hepatic storage, and/or liver concentration of a fat soluble vitamin in a post-menopausal woman or a lower animal by orally administering L-carnitine and a

BACKGROUND 1. Technical Field of the Invention The present invention relates to a method of producing a therapeutic agent for use in the prevention of cancer that arises from mutations to the BRCA1 and BRCA2 genes, i.e., breast and ovarian, and the treatment of several types of human diseases